Dr. Kafka joined Foundation Medicine in January 2013, bringing a variety of experiences in finance, operations, and strategic planning in work with biopharma companies focused on targeted therapies in oncology. Prior to joining Foundation Medicine, Dr. Kafka was chief operating officer and chief financial officer at Aileron Therapeutics, where he led the company’s operations, finance, and human resources functions. Before this, Dr. Kafka was vice president of finance at Infinity Pharmaceuticals (NASDAQ: INFI) where he led finance, investor and public relations and business operations. Earlier in his career, Dr. Kafka was senior director of finance at Millennium Pharmaceuticals, where he was a core member of the product team in driving strategic planning and alliance management efforts for VELCADE®, a novel targeted cancer therapeutic.

Dr. Kafka earned his Ph.D. from Harvard University and his B.A. from Stanford University.